Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Primary active transport

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Primary active transport. Displaying page 1 of 1.
    EudraCT Number: 2015-005536-17 Sponsor Protocol Number: UX007G-CL301 Start Date*: 2017-05-17
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1...
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10061032 Carbohydrate transport disorder LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002239-29 Sponsor Protocol Number: WI18274 Start Date*: 2006-03-06
    Sponsor Name:F. Hoffmann - La Roche AG
    Full Title: A phase II prospective, open label, randomized, active-controlled, parallel group, multi-center ‘proof of concept’ trial in adult patients with complicated skin and skin structure infections requir...
    Medical condition: Treatment of adult patients with complicated skin and skin structure infections requiring hospitalization.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) DE (Completed) LV (Completed) HU (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000048-73 Sponsor Protocol Number: AMT-101-201 Start Date*: 2020-09-24
    Sponsor Name:Applied Molecular Transport Inc.
    Full Title: A Combined Phase 2/3 12-week, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis
    Medical condition: Pouchitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10036463 Pouchitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002627-90 Sponsor Protocol Number: 3589 Start Date*: 2008-09-05
    Sponsor Name:Royal Liverpool and Broadgreen University Hospitals NHS Trust [...]
    1. Royal Liverpool and Broadgreen University Hospitals NHS Trust
    2. University of Liverpool
    Full Title: Intracellular boosting of HIV protease inhibitors through inhibition of transport - a novel strategy for potentiating HIV therapy
    Medical condition: This study is to evaluate the intracellular boosting effect of furosemide and dipyridamole of the HIV protease inhibitors in HIV positive patients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005057-87 Sponsor Protocol Number: 337HNAS21016 Start Date*: 2022-06-15
    Sponsor Name:Inventiva S.A.
    Full Title: A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of Lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin...
    Medical condition: Type 2 Diabetes (T2DM) with Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004082-25 Sponsor Protocol Number: D5130C00137 Start Date*: 2015-03-27
    Sponsor Name:Hellenic Cardiovascular Research Society
    Full Title: A multicenter, prospective, randomized, open label, blinded endpoint, active-comparator trial to assess the MIcrovascular integrity and left ventricular function Recovery after clopidogrel or Ticag...
    Medical condition: Patients with Myocardial Infarction with ST-segment elevation (STEMI) undergoing thrombolysis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001985-86 Sponsor Protocol Number: JX594-HEP024 Start Date*: 2016-09-29
    Sponsor Name:SillaJen Inc.
    Full Title: A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carc...
    Medical condition: Advanced Hepatocellular Carcinoma (HCC) without prior systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003771-35 Sponsor Protocol Number: UX007G-CL201 Start Date*: 2014-02-11
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10039911 Seizures (incl subtypes) HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) FR (Ongoing) HU (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000202-37 Sponsor Protocol Number: BUR02 Start Date*: 2018-10-09
    Sponsor Name:Kyowa Kirin Pharmaceutical Development Ltd
    Full Title: A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH)
    Medical condition: XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. This genetic deficiency is estimated to occur in about 1:20,000 live births (Burn...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002857-18 Sponsor Protocol Number: H9P-MC-LNBI Start Date*: 2009-02-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment with LY2216684 in Adult Patients with Major Depressive Disorder
    Medical condition: Patients with Major Depressive Disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision® (DSM-IV-TR; APA 2004),
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-005696-24 Sponsor Protocol Number: MS200095-0022 Start Date*: 2016-07-04
    Sponsor Name:Merck KGaA
    Full Title: A Phase II, single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (V...
    Medical condition: Advanced (stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Trial now transitioned) FR (Trial now transitioned) AT (Completed) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004443-20 Sponsor Protocol Number: HP-LY-CL-2063 Start Date*: 2018-05-07
    Sponsor Name:Herantis Pharma Plc
    Full Title: A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph nod...
    Medical condition: Secondary lymphedema associated with the treatment of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10036389 Postmastectomy lymphedema syndrome LLT
    20.0 100000004866 10025233 Lymphedema LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:07:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA